Diabetes, Vol 37, Issue 10 1432-1437, Copyright © 1988 by American Diabetes Association

ARTICLES

Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718 [corrected]

WS Zawalich, VA Diaz and KC Zawalich
Yale University School of Nursing, New Haven, CT 06536-0740.

The influence of L 364718 on islet responsiveness to sulfated cholecystokinin (CCK-8S) was investigated. In islets whose inositol-containing phospholipids were prelabeled during a 2-h incubation period, subsequent exposure to L 364718 (1 nM) significantly impaired the secretion of insulin usually noted in response to 200 nM CCK-8S in the simultaneous presence of 7 mM glucose. A higher level of the antagonist (10 nM) completely abolished insulin secretion. L 364718 (1-10 nM) reduced the efflux of 3H from myo-[2-3H]-inositol prelabeled islets in parallel with the reduction in secretion. L 364718 (10 nM) significantly reduced the accumulation of 3H-containing inositol phosphates usually noted with CCK-8S addition. L 364718, at levels 10- to 100-fold greater than those necessary to attenuate CCK-8S-induced insulin secretion, had no adverse effect on the insulin secretory response of freshly isolated islets to 10 mM glucose alone, 5 mM D-glyceraldehyde, 15 mM alpha-ketoisocaproate, or 50 ng/ml gastric inhibitory polypeptide. L 364718 (1000 nM) had no adverse influence on carbamylcholine (1 mM)-induced phosphoinositide hydrolysis. These results establish L 364718 as a potent and highly selective antagonist of cholecystokinin's stimulatory actions on beta-cells. Because of its potency, selectivity, and oral effectiveness, in vivo studies with L 364718, aimed at unraveling the pleiotropic effects of CCK-8S on glucose and insulin homeostasis, seem feasible.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. J. Meier, G. Kemmeries, J. J. Holst, and M. A. Nauck Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects Diabetes, July 1, 2005; 54(7): 2212 - 2218. [Abstract] [Full Text] [PDF]

				J. Morisset, S. Julien, and J. Laine Localization of Cholecystokinin Receptor Subtypes in the Endocine Pancreas J. Histochem. Cytochem., November 1, 2003; 51(11): 1501 - 1513. [Abstract] [Full Text] [PDF]

				B. Ahrén, J. J. Holst, and S. Efendic Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1043 - 1048. [Abstract] [Full Text]